246250 — SLS Bio Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for SLS Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	57.9	2,826	1,434	336	-4,904
Depreciation
Amortisation
Non-Cash Items	822	-2.93	1.72	300	599
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-21.3	-92.4	722	-246	827
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	2,258	4,034	3,436	1,726	-2,195
Capital Expenditures	-786	-735	-1,409	-1,500	-1,532
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	4.11	-809	-6,510	997	3,475
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-782	-1,543	-7,918	-502	1,944
Financing Cash Flow Items	-1.03	—	-302	-27.8	0
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-186	-2,345	4,777	-1,901	-615
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	1,290	146	295	-677	-866